Evidence map›Paper›PMID 31485618›Full record

ArticleMolecular medicine reports2019

Clofarabine‑phytochemical combination exposures in CML cells inhibit DNA methylation machinery, upregulate tumor suppressor genes and promote caspase‑dependent apoptosis.

Agnieszka Kaufman-Szymczyk, Katarzyna Majda, Agata Szuławska-Mroczek, Krystyna Fabianowska-Majewska, Katarzyna Lubecka

Open access · bronzeAbstract read
In one paragraph

Article in Molecular medicine reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.8field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 17 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Lunasin and Its Epigenetic Impact in Cancer Chemoprevention.International journal of molecular sciences · 2023
    Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Agnieszka Kaufman-SzymczykDepartment of Biomedical Chemistry, Faculty of Health Sciences, Medical University of Lodz, 92‑215 Lodz, Poland.
Katarzyna MajdaDepartment of Biomedical Chemistry, Faculty of Health Sciences, Medical University of Lodz, 92‑215 Lodz, Poland.
Agata Szuławska-MroczekDepartment of Biomedical Chemistry, Faculty of Health Sciences, Medical University of Lodz, 92‑215 Lodz, Poland.
Krystyna Fabianowska-MajewskaFaculty of Medicine, Lazarski University, 02‑662 Warsaw, Poland.
Katarzyna LubeckaDepartment of Biomedical Chemistry, Faculty of Health Sciences, Medical University of Lodz, 92‑215 Lodz, Poland.
Medical University of Lodz · PLUczelnia Łazarskiego · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Clofarabine (2‑chloro‑2'‑fluoro‑2'‑deoxyarabinosyladenine, CIF), a second‑generation 2'‑deoxyadenosine analog, possesses a variety of anti‑cancer activities, including the capacity to modulate DNA methylation marks. Bioactive nutrients, including resveratrol (RSV) and all‑trans retinoic acid (ATRA) have been indicated to regulate epigenetic machinery in malignant cells. The purpose of the current study was to evaluate whether the tested phytochemicals, RSV or ATRA, can improve the therapeutic epigenetic effects of CIF in chronic myeloid leukemia (CML) cells. The present study investigates, to the best of our knowledge, for the first time, the influence of CIF in combination with RSV or ATRA on the expression of relevant modifiers of DNA methylation machinery, including DNA Methyltransferase 1 (DNMT1) and Cyclin dependent kinase inhibitor 1A (CDKN1A) in CML cells. Subsequently, the combinatorial effects on promoter methylation and transcript levels of methylation‑silenced tumor suppressor genes (TSGs), including phosphatase and tensin homologue (PTEN) and retinoic acid receptor beta (RARB), were estimated using MSRA and qPCR, respectively. The tested TSGs were chosen according to bioinformatical analysis of publicly available clinical data of human DNA methylation and gene expression arrays in leukemia patients. The K562 cell line was used as an experimental CML in vitro model. Following a period of 72 h exposure of K562 cells, the tested combinations led to significant cell growth inhibition and induction of caspase‑3‑dependent apoptosis. These observations were accompanied by DNMT1 downregulation and CDKN1A upregulation, with a concomitant enhanced decrease in DNMT1 protein level, especially after ATRA treatment with CIF. Concurrent methylation‑mediated RARB and PTEN reactivation was detected. The results of the current study demonstrated that CIF that was used in combination with the tested phytochemicals, RSV or ATRA, exhibited a greater ability to remodel DNA methylation marks and promote cell death in CML cells. These results may support the application of CIF combinations with natural bioactive agents in anti‑leukemic epigenetic therapy.

Indexed as

Antineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsAntioxidantsApoptosisCell Line, TumorClofarabineCyclin-Dependent Kinase Inhibitor p21DNA (Cytosine-5-)-Methyltransferase 1DNA MethylationDrug SynergismEpigenesis, GeneticGene Expression Regulation, LeukemicHumansLeukemia, Myelogenous, Chronic, BCR-ABL PositiveResveratrolTretinoinAntineoplastic AgentsAntioxidantsCDKN1A protein, humanClofarabineCyclin-Dependent Kinase Inhibitor p21DNA (Cytosine-5-)-Methyltransferase 1DNMT1 protein, humanResveratrolTretinoin

Identifiers

PMID31485618
PMCPMC6755200
OpenAlexW2971189916

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.